Vivus vexed by birth defects with Qnexa component
23 December 2011
Donna Young
Please Login to read the full article.
23 December 2011
Donna Young
Please Login to read the full article.
RELATED CONTENT
NEWS
- Vivus jumps on FDA request to remove contraindication in proposed Qnexa label
- Vivus narrows indication for Qnexa obesity drug to FDA to enable Q2 2012 approval
- Vivus soars on FDA deal marking path forward for obesity drug
- Birth defects a concern, but cardio may dominate Qnexa's 2nd FDA panel
FEATURES
Other Informa Features
EVENTS
Today
The Rembrandt Hotel, London
07 June 2012
The Rembrandt Hotel, London
12 June 2012
Annecy, France
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
